<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04374578</url>
  </required_header>
  <id_info>
    <org_study_id>ZSE-202003</org_study_id>
    <nct_id>NCT04374578</nct_id>
  </id_info>
  <brief_title>Effect of Dulaglutide on Glycemic Variability in Patients With Type 2 Diabetes</brief_title>
  <acronym>DIVE</acronym>
  <official_title>Effect of Dulaglutide on Glycemic Variability in Patients With Type 2 Diabetes: A Multi-center Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glycemic variability will be assessed using continuous glucose monitor(CGM) in type 2
      diabetic patients who receive dulaglutide 1.5 mg/qw injection for 4 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glycemic fluctuation is a major problem in glucose control in diabetic patients. It is
      interesting to know that whether weekly GLP-1RA can improve glycemic variability in diabetic
      patients. The present study aims to assess the effect of dulaglutide on glycemic variability
      using continuous glucose monitor(CGM) (Libra, Abbott) in type 2 diabetic patients with 4
      weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 8, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Effect on glycemic variability</measure>
    <time_frame>one months</time_frame>
    <description>The FreeStyle Libre Pro (Abbott Co., Ltd) will be used to monitor glucose levels during the four weeks from the day before the first administration of the study drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect on Glycemic Control</measure>
    <time_frame>one months</time_frame>
    <description>It will be assessed at baseline and after one months of treatment to determine the anti-diabetic effect of dulaglutide</description>
  </secondary_outcome>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Type 2 Diabetes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dulaglutide 1.5 MG/ML</intervention_name>
    <description>Dulaglutide 1.5Mg qw sc injection for 4 weeks</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Type 2 diabetes come to the clinic who want to use dulaglutide and never used dulaglutide
        before
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fully understand the test content and possible adverse reactions and voluntarily
             participate in the trial and sign the informed consent form;

          -  Meet the World Health Organization(WHO) (1999) criteria for the diagnosis and
             classification criteria for type 2 diabetes;

          -  18 ≤ age ≤ 70 years old, male or female;

        Exclusion Criteria:

          -  Subjects with Type 1 diabetes mellitus or secondary diabetes mellitus (i.e. any type
             other than T2DM)

          -  Personal history or family history of thyroid medullary carcinoma or multiple
             endocrine neoplasia type 2 (MEN2).

          -  History of pancreatitis or considered clinically at significant risk of developing
             pancreatitis during the course of the study (e.g. due to symptomatic gallstones).

          -  History of significant gastrointestinal (GI) surgery that in the opinion of the
             investigator is likely to significantly affect upper GI or pancreatic function.

          -  Fasting triglyceride level more than 750 mg/dL at screening.

          -  Estimated Glomerular Filtration Rate (eGFR) less than 60 mL/minute/1.73 meter^2
             (calculated using the Schwartz equation) at screening.

          -  ALT more than 2.5x upper limit of normal (ULN) or Bilirubin more than 1.5xULN
             (isolated bilirubin more than 1.5xULN is acceptable if bilirubin is fractionated and
             direct bilirubin more than 35%) at screening.

          -  Use of a GLP-1receptor agonist at study entry and during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoying Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lin Zhao, MD</last_name>
    <phone>8602164041990</phone>
    <phone_ext>2023</phone_ext>
    <email>zhao.lin@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>180 Fenglin Road</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Zhao, MD</last_name>
      <phone>+8613917902849</phone>
      <email>zhao.lin@zs-hospital.sh.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 1, 2020</study_first_submitted>
  <study_first_submitted_qc>May 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2020</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dulaglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

